{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:15:48Z","timestamp":1777785348120,"version":"3.51.4"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi and Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jiac.2025.102669","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:25:58Z","timestamp":1740673558000},"page":"102669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The time to return-to-work in healthcare workers with COVID-19 treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2: An observational study utilizing pre-existing data from a single hospital"],"prefix":"10.1016","volume":"31","author":[{"given":"Makoto","family":"Katsuta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Karibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusaku","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Ariwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102669_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1254\/fpj.24017","article-title":"[Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA(\u00ae) Tablets 125 \u200dmg)]","volume":"159","author":"Tsuge","year":"2024","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.jiac.2025.102669_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2025.102669_bib6","article-title":"Healthcare worker access to molnupiravir: a case series","volume":"18","author":"O'Keeffe","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2025.102669_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1059880","article-title":"Can the nucleic acid Ct value of discharged patients infected with SARS-CoV-2 Omicron variant be 35?--A retrospective study on fluctuation of nucleic acid Ct values in SNIEC mobile cabin hospital","volume":"12","author":"Zhuang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiac.2025.102669_bib8","first-page":"250","article-title":"[Negative confirmation and infectivity estimation by quantitative antigen test of COVID-19]","volume":"71","author":"Kase","year":"2022","journal-title":"Jpn J of Med Tech"},{"key":"10.1016\/j.jiac.2025.102669_bib9","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102669_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13338","article-title":"Efficacy and safety of ensitrelvir for asymptomatic or mild covid-19: an exploratory analysis of a multicenter, randomized, phase 2b\/3 clinical trial","volume":"18","author":"Ohmagari","year":"2024","journal-title":"Influenza other respir viruses"},{"key":"10.1016\/j.jiac.2025.102669_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033024","article-title":"A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)","volume":"102","author":"Yotsuyanagi","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jiac.2025.102669_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105958","article-title":"Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial","volume":"229","author":"Yotsuyanagi","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiac.2025.102669_bib13","article-title":"Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19","author":"Takazono","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102669_bib14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/vaccines10081322","article-title":"Impact of COVID-19 vaccination on healthcare worker infection rate and outcome during SARS-COV-2 omicron variant outbreak in Hong Kong","volume":"10","author":"Zee","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jiac.2025.102669_bib15","first-page":"45","article-title":"[Safety and effectiveness of ensitrelvir for the treatment of COVID-19 in clinical practice \u2015A post-marketing surveillance (interim analysis)]","volume":"6","author":"Nakagawa","year":"2023","journal-title":"Precis Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:16:43Z","timestamp":1744424203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1341321X25000662"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102669","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The time to return-to-work in healthcare workers with COVID-19 treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2: An observational study utilizing pre-existing data from a single hospital","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102669"}}